drugset
drugset / Trial / NCT04582669

Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa

NCT04582669 ↗

Phase 4 Terminated 11 enrolled Montefiore Medical Center
RandomizedParallel-groupDouble-blindTreatment

Summary

Currently, there is limited evidence showing increased resolution of HS flares with higher doses of intralesional triamcinolone (ILTAC) as well as a difference in side effect profile between the doses. The goal of this study is to determine the efficacy of treating HS flares with ILTAC-10, ILTAC-20 and ILTAC-40 and to investigate the side effect profile for each dose.

Timeline

Start
2022-01-24
Primary completion
2022-10-12
Completion
2022-10-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Triamcinolone Other / unclassified 10 mg/ml Other
Comparator Triamcinolone Other / unclassified 20 mg/ml Other
Comparator Triamcinolone Other / unclassified 40 mg/ml Other

Indications

hidradenitis suppurativa